Results of AGM

IXICO plc

23 January 2026

 

23 January 2026

IXICO plc

("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	VOTES TOTAL	% ISC VOTED	VOTES WITHHELD
1	Reports and Accounts	58,472,204	99.99%	6,000	0.01%	58,478,204	63.10	1,700
2a	Re-election of Bram Goorden	58,465,677	99.99%	6,600	0.01%	58,472,277	63.10	7,627
2b	Re-election of Grant Nash	58,465,677	99.99%	6,600	0.01%	58,472,277	63.10	7,627
2c	Re-election of Mark Warne	58,465,677	99.99%	6,600	0.01%	58,472,277	63.10	7,627
2d	Re-election of Dr Dipti Amin	58,465,677	99.99%	6,600	0.01%	58,472,277	63.10	7,627
2e	Re-election of Kate Rogers	58,465,677	99.99%	6,600	0.01%	58,472,277	63.10	7,627
3	Re-appointment of  Moore Kingston Smith Auditors	58,475,004	100.00%	2,800	0.00%	58,477,804	63.10	2,100
4	Allotment of Securities	58,475,336	100.00%	1,800	0.00%	58,477,136	63.10	2,768
5	* Disapply Pre-Emption Provisions	58,354,629	99.79%	122,507	0.21%	58,477,136	63.10	2,768

* Special Resolution

For the purposes of section 341 of the Companies Act 2006, IXICO plc's total issued share capital with voting rights as at 6.30pm on 22 January 2026, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 92,668,598 ordinary shares.

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.    

For further information please contact:

IXICO plc	[phone]
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	[phone]
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

 

END